

Date: 22/04/2022

FREEDOM OF INFORMATION REQUEST FOI/016157 – Breast cancer

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

Abemaciclib (Verzenios) + aromatase inhibitor *
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
Alpelisib (Piqray) + Fulvestrant (Faslodex)
Atezolizumab (Tecentriq)**
Bevacizumab (Avastin)
Eribulin (Halaven)
Everolimus (Afinitor) + Exemestane
Fulvestrant (Faslodex) as a single agent
Gemcitabine + paclitaxel
Herceptin (Trastuzumab) + paclitaxel
Herceptin (Trastuzumab) as a single agent
Lapatinib (Tyverb)
Neratinib (Nerlynx)
Olaparib (Lynparza)
Palbociclib (Ibrance) + aromatase inhibitor*
Palbociclib (Ibrance) + Fulvestrant (Faslodex)
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab emtansine (Kadcyla)
Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

To see data we already have available please go to the Freedom of Information request disclosure log ' Disclosure log - The Dudley Group NHS Foundation Trust (dgft.nhs.uk) ' and in the search box type in breast cancer

Q2. For the above patients, how many of these received their first ever dose for each product line? - Not known, information would be recorded in a patient's medical records which are exempt under the FOI Act, Exemption Section 40 personal information